Good benefits, but terrible environment. - Avis employé Employé (anonyme) Merck

2,0
21 avr. 2012
Employé (anonyme)
Recommande
Approbation du PDG
Perspective commerciale

Avantages

Compared with other companies in the area, Merck has a good benefits package and above average compensation if you are willing to start out in a union role. Vacation time also builds up quickly.

Inconvénients

No development for employees. Your ability to achieve a work life balance will depend on your manager. Some people are given great flex schedules, while others are told that they need to come in early and stay late to cover those who have flex time. Middle management is grossly incompetent and over staffed while those displaying product and process knowledge are being laid off. Site head of quality operations stood in a cross-functional meeting and announced that he doesn't care how many 483s the company gets, as long as they save money. Morale is at an all time low, and managers encourage employees to work 10+ hours of unpaid OT each week by constantly reminding workers that there are more layoffs scheduled for this year.

Découvrez plus d’avis sur Merck

5,0
30 juin 2026
Recommande
Approbation du PDG
Perspective commerciale

Avantages

Excellent company to work with.

Inconvénients

No cons encountered so far

4,0
30 juin 2026
Recommande
Approbation du PDG
Perspective commerciale

Avantages

Great benefits like medical/dentist/vision, pension, stock option, 401k match. Co workers are excellent, pretty good on site symposiums, lot of diversity clubs/activities. Innovation is extremely welcomed. Diversity in research portfolio. AI/ML is heavily invested to make databases more efficient.

Inconvénients

Micro managing, especially within the biologics department, potentially others. Promotions are limited, and pay bump is poor. Company invests too much in buying companies rather than keeping talent - lay offs let go of great talented people. Merck is afraid of investing into exploratory biology and doesn’t take risk - they even admit they would rather see other companies clinical data or R&D data rather than taking a risk. Although it’s slow going in building new software, current databases are slow and needs much improvement. Extremely poor work/life balance.

Voir les avis par: Utile|Évaluation|Date|Tout